![](https://www.medicaldevice-network.com/wp-content/uploads/sites/23/2024/07/study-shutterstock_2095035964-430x241.jpg)
Merit Medical Systems has agreed to acquire medical device company EndoGastric Solutions, for a cash consideration of around $105m.
This acquisition includes EndoGastric’s EsophyX Z+ device, a non-pharmacological treatment for gastroesophageal reflux disease (GERD).
The device is designed to offer a minimally invasive solution to alleviate GERD symptoms by restoring the natural reflux barrier of the body.
A procedure, known as transoral incisionless fundoplication (TIF 2.0), is performed under endoscopic visualisation and is designed to reduce acid reflux that may lead to long-term health issues.
Additionally, TIF 2.0 can be paired with a surgical hiatal hernia repair in a combined procedure called concomitant transoral incisionless fundoplication (cTIF).
Merit chairman and CEO Fred Lampropoulos said: “This acquisition is consistent with our Continued Growth Initiatives. It enhances our product portfolio in existing clinical specialities while expanding our global footprint in the multi-billion-dollar gastrointestinal market.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
![](/wp-content/themes/goodlife-wp-B2B/assets/images/company-profile-unit.png)
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData“We look forward to helping more patients by providing clinicians with a sustained and minimally invasive treatment option for chronic GERD.”
Merit Medical said the assets acquired from EndoGastric Solutions reported revenues of approximately $26m for the 12-month period that ended on 31 December 2023.
Post-acquisition, these assets are projected to contribute revenues in the range of $13m to $15m from the closing date through 31 December 2024.
Lampropoulos added: “In addition to the strong strategic rationale, we believe the financial profile of this acquisition is compelling. While modestly dilutive to our full-year 2024 non-GAAP profitability given the partial-year contribution, we expect the acquisition to be accretive to our non-GAAP gross and operating margins, non-GAAP net income and non-GAAP EPS in the first full year post-closing.
Last month, Medtronic and Merit Medical Systems teamed up to distribute the Kyphon KyphoFlex unipedicular balloon catheter for treating VCFs [vertebral compression fractures] in the US.